이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal Cancer

2026년 11월 16일 업데이트: Lee, Soo Hyeon, Korea University Anam Hospital

A Phase 2, Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Erlotinib in Patients With EGFR-Amplified Metastatic Colorectal Cancer Who Have Failed or Are Not Eligible for Oxaliplatin- and Irinotecan-Based Chemotherapy

This phase II, open-label, single-arm clinical trial is designed to evaluate the efficacy and safety of a combination therapy with bevacizumab and erlotinib as a salvage treatment in patients with metastatic colorectal cancer who have failed or are intolerant to standard oxaliplatin- and irinotecan-based chemotherapy, and whose tumors harbor an EGFR copy number gain of 4 or higher confirmed by NGS testing. The primary objective is to evaluate progression-free survival (PFS), and secondary objectives include objective response rate (ORR), overall survival (OS), disease control rate (DCR), safety, and quality of life.

연구 개요

상세 설명

This study investigates the clinical benefit of combining an anti-VEGF agent (bevacizumab) with an EGFR tyrosine kinase inhibitor (erlotinib) in refractory metastatic colorectal cancer with EGFR amplification. Eligible patients will receive bevacizumab at 7.5 mg/kg intravenously every 3 weeks combined with daily oral erlotinib at 150 mg. Tumor assessments will be conducted periodically using RECIST version 1.1 to determine clinical outcomes, and toxicities will be graded according to NCI CTCAE version 5.0.

연구 유형

중재적

등록 (추정된)

39

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

19년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Histologically or cytologically proven metastatic/recurrent colorectal cancer who have failed or are intolerant to standard chemotherapy based on oxaliplatin and irinotecan (and if RAS wild-type, an anti-EGFR therapy).

  2. EGFR copy number gain ≥ 4 confirmed by NGS testing performed at the participating institution.

  3. Measurable disease per RECIST version 1.1 (measurable lesions are not mandatory for study entry).

  4. Age ≥ 19 years.

  5. ECOG performance status 0-2.

  6. Adequate bone marrow and organ function:

    • Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L
    • Hemoglobin (Hgb) ≥ 9.0 g/dL
    • Platelet count ≥ 75 x 10^9/L
    • Serum creatinine ≤ 1.5 x ULN or creatinine clearance > 30 mL/min
    • Total bilirubin ≤ 2.0 x ULN (subjects with biliary obstruction are eligible if criteria are met after appropriate biliary drainage)
    • AST and ALT ≤ 3 x ULN (or ≤ 5 x ULN if liver metastases are present)
  7. Adequate cardiac function: QTc ≤ 480 msec (if QTc > 480 msec, average QTc < 480 msec in triplicate measurements).

  8. Ability to swallow oral medication.

  9. Negative serum β-HCG pregnancy test within 14 days prior to study drug administration for female patients of childbearing potential.

  10. Agreement to use appropriate contraception methods as outlined in the protocol.

  11. Life expectancy ≥ 3 months.

  12. Signed and dated informed consent prior to any study-related procedures.

Exclusion Criteria:

  1. Pregnant or breastfeeding women.
  2. Prior history of combination therapy with an EGFR tyrosine kinase inhibitor and anti-VEGF blockade.
  3. Known hypersensitivity to the study drug components.
  4. Cytotoxic chemotherapy within 14 days, investigational drugs within 2 weeks or 5 half-lives, or monoclonal antibody therapy within 4 weeks prior to study entry.
  5. Uncontrolled severe infection.
  6. Severe medical or psychiatric conditions including active cardiac disease, uncontrolled hypertension, significant arrhythmias, or conditions prolonging QTc.
  7. Active central nervous system (CNS) metastases (unless radiologically stable, asymptomatic, and off steroids for at least 4 weeks; leptomeningeal disease is excluded).
  8. History of another primary malignancy (except adequately treated non-melanoma skin cancer, superficial cervical carcinoma, stage 1 bladder cancer, completely resected thyroid cancer, or other solid tumors with no evidence of recurrence for at least 36 months).
  9. Persistence of toxicities from prior anticancer therapy > Grade 1 (except alopecia).
  10. Extensive radiotherapy to the bone marrow within 4 weeks or limited radiotherapy within 2 weeks prior to study entry.
  11. Major surgery within 4 weeks prior to study entry or unrecovered from surgical side effects.
  12. Thrombotic or thromboembolic events within 6 months.
  13. History or evidence of bleeding disorders.
  14. Therapeutic use of maximum dose anticoagulants.
  15. Unhealed wounds, acute ulcers, or bone fractures.
  16. Abdominal fistula, gastrointestinal perforation, or active GI bleeding within 6 months.
  17. Urine dipstick protein ≥ 2+ with 24-hour urine protein > 1g.
  18. History or pathological findings of major GI surgery that may impair oral absorption.
  19. Evidence of active infection including Hepatitis B, Hepatitis C, or HIV (subjects with controlled or inactive HBV/HCV under specific protocol criteria are permitted).
  20. Conditions or diseases deemed by the investigator to contraindicate study participation.
  21. Medical, psychological, cognitive, or other conditions that impair the subject's ability to understand, consent, or comply with protocol procedures.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Bevacizumab plus Erlotinib

Participants will receive Bevacizumab at 7.5 mg/kg intravenously every 3 weeks combined with daily oral Erlotinib at 150 mg.

Administered at 7.5 mg/kg intravenously every 3 weeks.

다른 이름들:
  • 온베브지

Administered at 150 mg orally daily.

다른 이름들:
  • Eltinib

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression-Free Survival (PFS)
기간: From the first dose of study treatment until disease progression or death, assessed up to 12 months

PFS is calculated from the date of the first administration of the study drug to the date of documented disease progression or death from any cause.

From the first dose of study treatment until disease progression or death, assessed up to 12 months

2차 결과 측정

결과 측정
측정값 설명
기간
Objective Response Rate (ORR)
기간: Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months

Proportion of patients who achieve a Complete Response (CR) or Partial Response (PR) evaluated using RECIST version 1.1.

Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months
Overall Survival (OS)
기간: From the first dose of study treatment until death, assessed up to 1 year of survival follow-up

OS is calculated from the date of the first administration of the study drug to the date of death from any cause or the last follow-up date

From the first dose of study treatment until death, assessed up to 1 year of survival follow-up
Disease Control Rate (DCR)
기간: Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months

Proportion of patients who achieve CR, PR, or stable disease (SD) maintained for at least 6 weeks after study drug administration

Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months
Duration of Response (DOR)
기간: From initial response until documented disease progression, assessed up to approximately 12 months

Calculated from the time initial response (CR or PR) is documented until the date of progressive disease

From initial response until documented disease progression, assessed up to approximately 12 months
Time to Response (TTR)
기간: From the first dose of study treatment until the first documented response, assessed up to approximately 12 months

Calculated from the first dose of study treatment to the date of initial response (CR or PR)

From the first dose of study treatment until the first documented response, assessed up to approximately 12 months
Safety and Tolerability
기간: From the first dose of study treatment through 28 days after the last dose of study treatment, up to approximately 13 months

Evaluated by type, frequency, and severity of adverse events graded according to NCI CTCAE version 5.0

From the first dose of study treatment through 28 days after the last dose of study treatment, up to approximately 13 months
Quality of Life (QoL) EORTC QLQ-C30
기간: Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months

Assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months
Quality of Life (QoL) CR26
기간: Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months

Assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (CR26)

Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2027년 1월 4일

기본 완료 (추정된)

2028년 1월 31일

연구 완료 (추정된)

2030년 1월 31일

연구 등록 날짜

최초 제출

2026년 11월 10일

QC 기준을 충족하는 최초 제출

2026년 11월 16일

처음 게시됨 (실제)

2026년 11월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 17일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 16일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Yes. De-identified individual participant data underlying the results reported in this article, after de-identification, will be shared beginning 3 months and ending 5 years following article publication to researchers who provide a methodologically sound proposal. Proposals should be directed to the corresponding author. Data getters will be required to sign a data access agreement.

IPD 공유 기간

Beginning 3 months and ending 5 years following article publication.

IPD 공유 액세스 기준

De-identified individual participant data will be shared with researchers who provide a methodologically sound proposal to achieve the aims of the approved proposal. Proposals should be directed to the corresponding author. Data requesters will be required to sign a data access agreement.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다